Samuel Kintz Sells 924 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 924 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $30.00, for a total value of $27,720.00. Following the sale, the chief executive officer now directly owns 1,002,892 shares of the company’s stock, valued at approximately $30,086,760. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Wednesday, October 9th, Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.15, for a total value of $470,386.50.
• On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.50, for a total value of $75,075.00.
• On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $335,787.06.
• On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.54, for a total transaction of $14,486.04.
• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Trading Up 0.0 %

ELVN opened at $28.98 on Friday. The stock has a market capitalization of $1.36 billion, a P/E ratio of -15.02 and a beta of 1.10. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $30.03. The firm’s fifty day simple moving average is $24.62 and its 200 day simple moving average is $22.93.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its position in shares of Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. First Turn Management LLC bought a new stake in Enliven Therapeutics during the 2nd quarter worth about $9,657,000. Marshall Wace LLP acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth about $4,489,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $2,020,000. Finally, Bank of New York Mellon Corp increased its position in shares of Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.